<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097925</url>
  </required_header>
  <id_info>
    <org_study_id>DORAGEN</org_study_id>
    <secondary_id>2018-003921-27</secondary_id>
    <nct_id>NCT04097925</nct_id>
  </id_info>
  <brief_title>Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals</brief_title>
  <official_title>Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the ability of Doravirine to penetrate the genital tract and&#xD;
      suppress viral replication and provide evidence for the use of Doravirine as part of&#xD;
      treatment strategies as prevention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  To determine Doravirine concentrations in seminal plasma and cervicovaginal fluid in&#xD;
           HIV-1 infected male and female individuals receiving antiretroviral therapy (ATR) with&#xD;
           Doravirine plus Descovy®.&#xD;
&#xD;
        -  To evaluate HIV-1 viral load in seminal plasma and cervicovaginal fluid in HIV-1&#xD;
           infected male and female individuals receiving ART with Doravirine plus Descovy®.&#xD;
&#xD;
      Study Phase:&#xD;
&#xD;
      Phase II&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Open label, single arm, single center, prospective study.&#xD;
&#xD;
      Study Disease:&#xD;
&#xD;
      HIV-1 infection&#xD;
&#xD;
      Study Endpoints:&#xD;
&#xD;
        -  Concentration of Doravirine in seminal plasma and cervicovaginal fluid in HIV-1 infected&#xD;
           male and female individuals, respectively, 8 weeks after switching to Doravirine plus&#xD;
           Descovy®.&#xD;
&#xD;
        -  HIV-1 RNA in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female&#xD;
           individuals, respectively, 8 weeks after switching to Doravirine plus Descovy®.&#xD;
&#xD;
      Target Population:&#xD;
&#xD;
      Male and female adult HIV-1 infected patients receiving standard ART with tenofovir&#xD;
      alafenamide/emtricitabine (TAF/FTC), tenofovir disoproxil fumarate/emtricitabine or&#xD;
      abacavir/lamivudine , plus an non-nucleoside reverse transcriptase inhibitor, a boosted&#xD;
      protease inhibitor or an integrase inhibitor during at least 3 months, with plasma HIV-1 RNA&#xD;
      suppression (&lt;40 copies/mL) during at least 6 months.&#xD;
&#xD;
      Number of Subjects Planned:&#xD;
&#xD;
      15 male and 15 female individuals.&#xD;
&#xD;
      Study duration:&#xD;
&#xD;
      16 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with Doravirine administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC) and administered orally once daily.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Doravirine in seminal plasma fluid</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Concentration of Doravirine in seminal plasma fluid in HIV-1 infected male individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Doravirine in cervicovaginal fluid</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Concentration of Doravirine in cervicovaginal fluid in HIV-1 infected female individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification number of copies / mL of HIV in seminal plasma</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Quantification of copies / mL of HIV in seminal plasma in HIV-1 infected male individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification number of copies / mL of HIV in cervicovaginal fluid</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Quantification of copies / mL of HIV in cervicovaginal fluid in HIV-1 infected female individuals</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine 100 mg tablet</description>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Descovy</intervention_name>
    <description>Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet</description>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <other_name>TAF/FTC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Asymptomatic, HIV-1 infected individuals ≥ 18 years of age.&#xD;
&#xD;
          2. Be on a stable ART consisting of TAF/FTC, tenofovir disoproxil fumarate/emtricitabine&#xD;
             or abacavir/lamivudine, plus an non-nucleoside reverse transcriptase inhibitor, a&#xD;
             boosted protease inhibitor or an integrase inhibitor, continuously for at least 3&#xD;
             consecutive months preceding the screening visit.&#xD;
&#xD;
          3. Plasma HIV-1 RNA &lt;40 copies/mL for at least 6 months at the Screening visit.&#xD;
&#xD;
          4. Signed and dated written informed consent prior to inclusion.&#xD;
&#xD;
          5. Female Subjects of Childbearing Potential must agree to utilize a highly effective&#xD;
             method of contraception during heterosexual intercourse from the screening visit&#xD;
             throughout the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hepatic impairment (Child-Pugh Class C)&#xD;
&#xD;
          2. Ongoing malignancy&#xD;
&#xD;
          3. Active opportunistic infection&#xD;
&#xD;
          4. Resistance to any of the antiretroviral (ARV) included in the study or history of&#xD;
             virologic failure with risk of resistance selection to any of the study drugs.&#xD;
&#xD;
          5. Any verified Grade 4 laboratory abnormality&#xD;
&#xD;
          6. ALT or AST ≥ 3xULN and/or bilirubin ≥ 1.5xULN&#xD;
&#xD;
          7. Severe renal impairment (Estimated creatinine filtration rate &lt;50mL/min).&#xD;
&#xD;
          8. Females who are pregnant (as confirmed by positive serum pregnancy test) or&#xD;
             breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Podzamczer Palter, PhD Chief</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arkaitz Imaz, PhD</last_name>
    <phone>+34932607667</phone>
    <phone_ext>2883</phone_ext>
    <email>aimaz@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Manuel Tiraboschi, PhD</last_name>
    <phone>+34932607667</phone>
    <phone_ext>2885</phone_ext>
    <email>jmtiraboschi@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Morenilla</last_name>
      <phone>+34933359011</phone>
      <phone_ext>2913</phone_ext>
      <email>smorenilla@bellvitgehospital.cat</email>
    </contact>
    <contact_backup>
      <last_name>Laura Acerete</last_name>
      <phone>+34933359011</phone>
      <phone_ext>2876</phone_ext>
      <email>lacerete@bellvitgehospital.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Podzamczer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arkaitz Imaz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Manuel Tiraboschi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</investigator_affiliation>
    <investigator_full_name>Daniel Podzamczer</investigator_full_name>
    <investigator_title>Chief of the HIV and STD Unit (Infectious Disease Service)</investigator_title>
  </responsible_party>
  <keyword>Doravirine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

